Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00696384 · ClinicalTrials.gov registry record · Phase 3
A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 418
- Enrollment target
NCT00696384: Completed Phase 3 study, sponsored by Takeda.
NCT00696384 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 418 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (46% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00696384, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 418 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the long term safety and tolerability of azilsartan medoxomil, once daily (QD), in participants with Essential Hypertension.
Primary Outcome
The change in sitting clinic diastolic blood pressure measured at final visit or week 32 from Double-blind Baseline/Week 26. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements. Each participant's blood pressure at the Final Visit/Week 26 of the open-label phase represented their Baseline blood pressure for the double-blind reversal phase.
Interventions
- DRUG Placebo
- DRUG Azilsartan medoxomil
- DRUG Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 418 participants |
| Start Date | 2007-06 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
What the finished NCT00696384 record still lists
NCT00696384 is an interventional study that assigns participants to a tested intervention. The registered 418 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (46% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00696384 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00696384 about?
NCT00696384 is a clinical study titled "A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension". The purpose of this study is to determine the long term safety and tolerability of azilsartan medoxomil, once daily (QD), in participants with Essential Hypertension.
What is the current status of trial NCT00696384?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 418 participants. The study started on 2007-06. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00696384?
The interventions under investigation include: Placebo (DRUG), Azilsartan medoxomil (DRUG), Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications. (DRUG).
Who is sponsoring clinical trial NCT00696384?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00696384's enrollment target sits among peer trials
418 900th of 2000 higher than 1,099 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03135886 · 418 participants · NA
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
- NCT05579639 · 419 participants · Phase 2
Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant
- NCT06169735 · 417 participants · Phase 4
Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation
- NCT06699901 · 417 participants
Antibiotic Concentrations After MassivE Transfusion Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia